158 related articles for article (PubMed ID: 33005849)
21. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
22. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy plus surgery for high-risk advanced gastric cancer: long-term results of KDOG1001 trial.
Hosoda K; Katada C; Ishido K; Niihara M; Ushiku H; Sakuraya M; Washio M; Wada T; Watanabe A; Harada H; Sato T; Tajima H; Kaizu T; Kosaka Y; Kato H; Sengoku N; Tanaka K; Naito T; Kumamoto Y; Sangai T; Tanabe S; Koizumi W; Yamashita K; Hiki N
Langenbecks Arch Surg; 2020 Sep; 405(6):777-785. PubMed ID: 32617667
[TBL] [Abstract][Full Text] [Related]
24. A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer.
Tanaka Y; Kunisaki C; Izumisawa Y; Makino H; Kimura J; Sato S; Miyamoto H; Kosaka T; Ono HA; Takahashi M; Sato K; Akiyama H; Endo I
Anticancer Res; 2018 Oct; 38(10):6015-6021. PubMed ID: 30275234
[TBL] [Abstract][Full Text] [Related]
25. Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer.
Kanaji S; Suzuki S; Matsuda Y; Hasegawa H; Yamamoto M; Yamashita K; Oshikiri T; Matsuda T; Nakamura T; Sumi Y; Kakeji Y
Ann Gastroenterol Surg; 2018 Nov; 2(6):400-405. PubMed ID: 30460342
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002).
Kinoshita T; Sasako M; Sano T; Katai H; Furukawa H; Tsuburaya A; Miyashiro I; Kaji M; Ninomiya M
Gastric Cancer; 2009; 12(1):37-42. PubMed ID: 19390930
[TBL] [Abstract][Full Text] [Related]
27. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
[TBL] [Abstract][Full Text] [Related]
28. Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case.
Watanabe T; Yoshikawa T; Kameda Y; Aoyama T; Hayashi T; Ogata T; Cho H; Tsuburaya A; Morita S; Miyashita Y; Sakamoto J
Surg Today; 2012 Oct; 42(10):983-7. PubMed ID: 22398719
[TBL] [Abstract][Full Text] [Related]
29. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
Kakeji Y; Yoshida K; Kodera Y; Kochi M; Sano T; Ichikawa W; Lee SW; Shibahara K; Shikano T; Kataoka M; Ishiguro A; Ojima H; Sakai Y; Musha N; Takase T; Kimura T; Takeuchi M; Fujii M
Gastric Cancer; 2022 Jan; 25(1):188-196. PubMed ID: 34351555
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3).
Kurokawa Y; Matsuyama J; Nishikawa K; Takeno A; Kimura Y; Fujitani K; Kawabata R; Makari Y; Terazawa T; Kawakami H; Sakai D; Shimokawa T; Satoh T
Gastric Cancer; 2021 Mar; 24(2):428-434. PubMed ID: 32779034
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II
Xue K; Ying X; Bu Z; Wu A; Li Z; Tang L; Zhang L; Zhang Y; Li Z; Ji J
Chin J Cancer Res; 2018 Oct; 30(5):516-525. PubMed ID: 30510363
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes.
Oyama K; Fushida S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Tani T; Fujimura T; Ohta T
J Surg Oncol; 2012 May; 105(6):535-41. PubMed ID: 22006649
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of multidisciplinary therapy combining neoadjuvant chemotherapy with S-1 plus cisplatin and postoperative sequential chemotherapy in patients with scirrhous gastric cancer.
Oshima T; Kunisaki C; Sato T; Yamada R; Fujii S; Rino Y; Masuda M; Imada T
Hepatogastroenterology; 2012; 59(117):1638-42. PubMed ID: 22115800
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer.
Tsuburaya A; Nagata N; Cho H; Hirabayashi N; Kobayashi M; Kojima H; Munakata Y; Fukushima R; Kameda Y; Shimoda T; Oba K; Sakamoto J
Cancer Chemother Pharmacol; 2013 May; 71(5):1309-14. PubMed ID: 23463482
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
36. FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.
Zhang S; Yan D; Sun Q; Du T; Cao D; Yang Y; Yuan B; Li H; Jiang X; Song C
Can J Gastroenterol Hepatol; 2020; 2020():1702823. PubMed ID: 32566545
[TBL] [Abstract][Full Text] [Related]
37. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Kurokawa Y; Hamakawa T; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
Anticancer Res; 2015 Apr; 35(4):2223-8. PubMed ID: 25862882
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Okamoto K; Makino I; Nakamura K; Miyashita T; Tajima H; Takamura H; Ninomiya I; Ohta T
Eur J Surg Oncol; 2015 Oct; 41(10):1354-60. PubMed ID: 26028256
[TBL] [Abstract][Full Text] [Related]
39. [A Case of Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil, Leading to a Pathological Complete Response].
Kawasaki K; Takeuchi D; Kaneko T; Miura S; Kamiya J; Miyahara Y; Yoshimura K; Ogata A
Gan To Kagaku Ryoho; 2017 Nov; 44(11):1017-1020. PubMed ID: 29138379
[TBL] [Abstract][Full Text] [Related]
40. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
